Invasive aspergillosis in the recipients of liver retransplantation

Liver Transplantation

Volumn 12, Issue 8, 2006, Pages 1205-1209

  Singh, Nina ^a,b   Pruett, Timothy L ^c   Houston, Sally ^d   Muñoz, Patricia ^e   Cacciarelli, Thomas V ^a,b   Wagener, Marilyn M ^a   Husain, Shahid ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; TACROLIMUS;

ADULT; ARTERY THROMBOSIS; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HEPATIC ARTERY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; MALE; MEDICAL DECISION MAKING; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RETRANSPLANTATION; RISK ASSESSMENT; TIME;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; LIVER TRANSPLANTATION; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33745595287     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20756     Document Type: Article

References (20)

1. Fortun JP, Martin-Davila P, Moreno S, de Vicente E, Nuno J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002;8:1065-1070.
2. Gavalda J, Len O, San Juan R, Aguado J, Fortun J, Lumbreras C, et al., for RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005;41:52-59.
3. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-49.
4. Hellinger WC, Bonatti H, Yao JD, Alverez S, Brumble LM, Keating MR, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005;11:656-662.
5. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997;64:716-720.
6. Postma R, Haagsma EB, Peeters PMJG, Van den Berg AP, Slooff MJH. Retransplantation of the liver in adults: outcome and predictive factors for survival. Transpl Int 2004; 17:234-240.
7. Fortun J, Martin-Davila P, Moreno S, Barcena R, de Vicente E, Honrubia A, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003;52:813-819.
8. Singh N, Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003;36:46-52.
9. Singh N, Limaye A, Safdar N, Forrest G, Pursell K, Munoz P, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients (abstract M717). Transplantation 2006;81:320-326.
10. Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Malinchoc M, Benson JT, et al. Hepatic retransplantation in cholestatic liver disease: Impact of the interval to retransplantation on survival and resource utilization. Hepatology 1999;30:395-400.
11. Busuttil RW, Farmer DA, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades. a single-center experience. Ann Surg 2005:241:905-918.
12. Ascioglu S, Rex JH, Bennett JE, Billie J, Croksert F, Denning DW, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
13. Reed A, Howard RJ, Fujita S, Foley DP, Langham MR, Schold JD, et al. A single-center outcome and financial analysis. Transplant Proceed 2005;37:1161-1163.
14. Azoulay D, Linhares MM, Huguet E, Delvart V, Castaing D, Adam R, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002:236:713-721.
15. Rosen HR, Madden JP, Martin PA. A model to predict survival following liver retransplantation. Hepatology 1999;19:365.
16. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005;11:434-440.
17. Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl 2003;9:897-904.
18. Burton JR Jr, Rosen HR. Retransplantation for hepatitis C: what do we really know? Liver Transpl 2004;10:1504-1506.
19. Hebart H, Bollinger C, Fisch P, Sarefati J, Meisner C, Baur M, et al. Analysis of T-cell responses to Aspergillus-fumigatus antigens in healthy individual and patients with hematologic malignancies. Blood 2003; 100:4521-4528.
20. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, Burchielli E, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003;102:3807-3814.